You are here

  • Home
  • Archive
  • Volume 17, Issue 1
  • A shorter interval between menarche and first sexual intercourse is associated with increased risk of high-grade cervical disease

Article Text

Article menu
Download PDFPDF
Women's health
Cohort study
A shorter interval between menarche and first sexual intercourse is associated with increased risk of high-grade cervical disease
  1. Jennifer S Smith
  1. Department of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, USA
  1. Correspondence to : Dr Jennifer S Smith
    Department of Epidemiology, UNC Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, 2103 McGavran-Greenberg, 135 Dauer Drive, Campus Box 7435, Chapel Hill 27599, USA; jennifers{at}unc.edu

https://doi.org/10.1136/eb-2013-101235

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ruiz AM, Ruiz JE, Gavilanes AV, et al. for the FUTURE I and II Study Group. Proximity of first sexual intercourse to menarche and risk of high-grade cervical disease. J Infect Dis 2012;206:1887–96.OpenUrlCrossRefPubMed

    Implications for practice and research

    • Female adolescents with a shorter duration between the age of menarche and first sexual intercourse are at an increased risk of high-grade cervical disease.

    • Clinical counselling should include clear recommendations to obtain human papillomavirus (HPV) vaccination well before first intercourse to reduce the future risk of high-grade cervical lesions among sexually naïve female adolescents.

    Context

    Ruiz and colleagues present associations between a shorter interval between menarche and first sexual intercourse on subsequent risk of high-grade cervical intraepithelial neoplasia (CIN-2+) or adenocarcinoma in situ among young women (16–23 years), in phase III randomised controlled trials (RCTs) in Colombia …

    View Full Text

    Footnotes

    • Competing interests JSS has received unrestricted grants and consultancies from GSK or Merck Corporation over the past 5 years.